Loading cancer entity…
Loading cancer entity…
Variants & evidence
1 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|
| BRCA1 Mutation + BRCA2 MutationBRCA2BRCA11 | |||||||
| Niraparib | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11305In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enroll… (full text at CIViC) PMID 27717299 · Mirza et al., 2016 · Open in CIViC | civic |
Data updated 18 minutes agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.